Provided by Tiger Fintech (Singapore) Pte. Ltd.

Disc Medicine

87.17
-2.7700-3.08%
Post-market: 87.450.2800+0.32%19:55 EDT
Volume:1.34M
Turnover:117.16M
Market Cap:3.03B
PE:-19.23
High:90.91
Open:90.19
Low:85.71
Close:89.94
52wk High:95.95
52wk Low:30.82
Shares:34.77M
Float Shares:28.68M
Volume Ratio:1.79
T/O Rate:4.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5319
EPS(LYR):-3.9613
ROE:-26.36%
ROA:-17.95%
PB:4.93
PE(LYR):-22.01

Loading ...

Shares of Some US Drug Developers up After FDA Announces Recipients of National Priority Vouchers

THOMSON REUTERS
·
Oct 17

Revolution Medicines up 6%, Achieve Life Sciences up 22.1%, Disc Medicine up 19.2%

THOMSON REUTERS
·
Oct 17

Sector Update: Health Care Stocks Mixed Premarket Friday

MT Newswires Live
·
Oct 17

Cantor Fitzgerald Sticks to Their Buy Rating for Disc Medicine (IRON)

TIPRANKS
·
Oct 17

Disc Medicine to Present Phase 1b Trial Data of DISC-0974 for Anemia in CKD Patients at 2025 ASN Kidney Week

Reuters
·
Oct 17

Disc Medicine Is Maintained at Outperform by Wedbush

Dow Jones
·
Oct 17

Wedbush Adjusts Price Target on Disc Medicine to $110 From $90, Maintains Outperform Rating

MT Newswires Live
·
Oct 17

Disc Medicine price target raised to $110 from $90 at Wedbush

TIPRANKS
·
Oct 17

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM) and Disc Medicine (IRON)

TIPRANKS
·
Oct 17

24H|Disc Medicine Surged 19%; Praxis Precision Rose 7%; Rare Earth Stocks Kept Dropping. UAMY And USA Rare Earth Fell 7%

Tiger Newspress
·
Oct 17

Disc Medicine Gets FDA Commissioner's National Priority Voucher for Drug Candidate

MT Newswires Live
·
Oct 17

Disc Medicine receives CNPV from FDA for Bitopertin

TIPRANKS
·
Oct 17

FDA: Anticipates Announcing Another Group of Commissioner’s National Priority Voucher Recipients in the Coming Months

THOMSON REUTERS
·
Oct 17

FDA: Products Nominated for National Priority Vouchers Include Bitopertin for Porphyria, Ketamine for Domestic Manufacturing of a General Anesthetic

THOMSON REUTERS
·
Oct 17

Disc Medicine Director Makes a Multi-Million Dollar Stock Sale!

TIPRANKS
·
Oct 10

Disc Medicine Director Kevin Bitterman Reports Sale of Common Shares

Reuters
·
Oct 10

Disc Medicine Board Member Mona Ashiya Resigns

TIPRANKS
·
Oct 07

Buy Rating Affirmed for Disc Medicine Amid Promising Bitopertin Prospects in EPP Treatment

TIPRANKS
·
Oct 06

Promising Developments and Positive Trials Support Buy Rating for Disc Medicine’s Bitopertin

TIPRANKS
·
Oct 01

Disc Medicine submits NDA to FDA for bitopertin in patients with EPP

TIPRANKS
·
Sep 30